Leukocyte stem cell therapy - Enlivex Therapeutics

Drug Profile

Leukocyte stem cell therapy - Enlivex Therapeutics

Alternative Names: Allocetra; ApoCell; leucocyte-stem-cell-therapy-Enlivex-Therapeutics

Latest Information Update: 23 Jan 2016

Price : $50

At a glance

  • Originator Hadassah Medical Organization
  • Developer Enlivex Therapeutics; Hadassah Medical Organization
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease

Highest Development Phases

  • Phase II Inflammation
  • Phase I/II Graft-versus-host disease
  • Preclinical Crohn's disease; Gout; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 23 Jan 2016 Preclinical trials in Rheumatoid arthritis, Gout and Multiple sclerosis in Israel (IV) before January 2016 (Enlivex Therapeutics Pipeline, January 2016)
  • 06 Jan 2016 Phase-II clinical trials in Inflammation (Prevention) in Israel (IV)
  • 06 Jan 2016 Preclinical development for Crohn's disease and Transplant rejection (solid organ) is ongoing in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top